KEYNOTE 991
Patient Summary

This clinical trial is for men with Metastatic Hormone- Sensitive prostate cancer (mHSPC) whose prostate cancer has responded to Androgen Deprivation Therapy (ADT).  

Why is this study being done?

This study is trying to find out if an investigational medication in combination with enzalutamide plus ADT is safe and can help stop or slow down this type of prostate cancer in comparison to ADT and enzalutamide alone. 

The treatments being studied:

This clinical trial is studying an investigational medication called Pembrolizumab (also known as MK-3475) in combination with enzalutamide and ADT. Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. This immunotherapy is FDA approved to treat other types of cancer but is not approved to treat mHSPC. Before deciding to participate, you should make sure you understand the potential side effects or risks of participating in the study. These will be explained to you by the study doctor. If there is anything you do not understand, you are encouraged to ask the study doctor.
For more information, 
click here
Organization: Merck

If you are interested in this trial, review the following:

Register your interest or comments about this trial with PHEN

PHEN Contact: 617-481-4020*

Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor. 















PHEN,Inc. © 2020 All rights reserved